Elenco degli articoli con argomento «Dupilumab»
Dermatologia05 mar 2024
Dupilumab treatment improves signs, symptoms, quality of life
Despite high disease burden, systemic treatment options for patients with atopic hand and/or foot dermatitis (H/F AD) are limited
05 mar 2024
Dupilumab for Treatment of Prurigo Nodularis
Prurigo nodularis (PN) is a persistent and inflammatory dermatological condition characterized by chronic
29 set 2023
Efficacy and safeness of tralokinumab in patients with atopic dermatitis
Efficacy and safeness of tralokinumab in patients with atopic dermatitis who developed conjunctivitis under dupilumab: A case series
31 ago 2023
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib
Characterization of upadacitinib use and switching from dupilumab to upadacitinib among patients with moderate-to-severe atopic dermatitis (AD) is needed.
05 giu 2023
Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis
Narrow-band (NB) UVB and UVA1 have been successfully used for the treatment of atopic dermatitis (AD) since the 1980s
17 apr 2023
The impact of dupilumab
Skin barrier dysfunction plays an important role in atopic dermatitis (AD) aetiopathogenesis
20 feb 2023
Treatment of Severe Atopic Dermatitis with Dupilumab
Atopic dermatitis is a chronic inflammatory intensively pruritic skin disease.
13 dic 2022
Comparison of real-world treatment outcomes of systemic immunomodulating
Few data exist on differences in treatment effectiveness and safety in atopic dermatitis patients of different skin types.
07 dic 2022
Treatment of chronic hand eczema with dupilumab
Treatment of chronic hand eczema with dupilumab - a retrospective follow-up study
03 ott 2022
Dupilumab in children aged 6 months to younger than 6 years
Background Current systemic treatments for children younger than 6 years with moderate-to-severe atopic dermatitis
15 set 2022
Efficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus
Dupilumab has demonstrated a great reduction in chronic pruritus that is the hallmark of atopic dermatitis
09 mag 2022
Moderate-to-severe atopic dermatitis in adolescents
Moderate-to-severe atopic dermatitis (AD) in the adolescence is a high burden disease and its treatment can be very challenging
18 apr 2022
Th2 IL-4/IL-13 dual blockade with Dupilumab is linked to some Emergent
Dupilumab, an IL-4/IL-13 receptor blocker, has been linked to emergent seronegative inflammatory arthritis and psoriasis that form part of the spondyloarthropathy (SpA) spectrum.
11 ott 2021
Phase 2a randomized clinical trial of dupilumab
Treatments for alopecia areata (AA) patients with extensive scalp hair loss are limited
29 mar 2021
Treatment of Grover Disease With Dupilumab
Treatment of Grover Disease With Dupilumab
04 mar 2021
A 48-week update
A 48-week update of a multicentre real-life experience of dupilumab in adult patients
24 feb 2021
A Short Cycle of Narrow-Band UVB
Since the best clinical response to dupilumab is achieved after 12-16 weeks
11 nov 2020
Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis
Real‐world effectiveness and tolerability of dupilumab in adult atopic dermatitis: A single centre, prospective one‐year observational cohort study of the first 100 patients treated
20 ott 2020
Long‐term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients
Dupilumab, an inhibitor of interleukin (IL)‐4/13 activity, is a biological agent approved for the treatment of moderate‐to‐severe atopic dermatitis (AD)
14 set 2020
A phase 2, open‐label study of single dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis
pharmacokinetics, safety and efficacy